Tresiba(R) Showed an Overall Lower Risk of Hypoglycaemia and S...
BARCELONA, Spain, September 19, 2019, /PRNewswire-AsiaNet/-- According to new data from the CONCLUDE head-to-head trial, Tresiba(R) (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 i...
Authors: LATEST ASIANET NEWS RELEASES